Clinical Trial Update: Comparative Bioavailability - Gender Effect - Single and Multiple Ascending Dose Safety and Pharmacokinetic Study of GFT505 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, pharmacokinetics, and gender effects of GFT505 (elafibranor) after single and multiple ascending doses; the trial has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiovascular Disease
• Dyslipidemia
• Metabolic Syndrome
• Obesity
• Type 2 Diabetes Mellitus

Drugs mentioned

• GFT505

Snippet

Sponsor: Genfit | Conditions: Type 2 Diabetes, Diabetes Mellitus, Type 2 | Phase 1 | Status: COMPLETED